Tobacco Use Disorder: Clinical Trials

95 trials for Tobacco Use Disorder, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

75 completed, 8 withdrawn, 5 recruiting, 5 terminated. 95 Phase 1, 27 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 195Completed 75, Withdrawn 8, Recruiting 5, Terminated 5, Unknown 2
Phase 227Completed 20, Terminated 3, Withdrawn 3, Recruiting 1

Follow Tobacco Use Disorder: new trials by email Literature Review of Tobacco Use Disorder trials Research Report on Tobacco Use Disorder

Trials (filtered) newest first · largest first

All 95 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers
ATI-1013 (0.2 g), ATI-1013 (0.8 g), ATI-1013 (3.2 g) - Thromboangiitis Obliterans (Buerger's Disease)
Phase 1RecruitingAntidote Therapeutics, Inc152025-10-012025-10-15
Effects of Cannabidiol on Stress and Nicotine Withdrawal
Epidiolex - CBD, Stress
Phase 1RecruitingJohns Hopkins University902025-08-252026-08-10
Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviors
quitSTART Mobile Application, Chatbot Feature in quitSTART Mobile Application - Nicotine Vaping, Nicotine Use Disorder
Phase 1TerminatedWashington University School of Medicine262025-06-042026-10-26
Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine
(S)-Nicotine, (R)- nicotine, Racemic nicotine - Nicotine Dependence, Nicotine Vaping
Phase 1RecruitingUniversity of California, San Francisco182024-12-062026-05-14
Overcoming Nicotine Dependence to Enable Quitting
Nicotine Replacement Therapy (NRT) Sampling, Practice Quitting (PQ) Counseling, Motivational Interviewing (MI) Counseling - Tobacco Use, Smoking Cessation
Phase 1 / Phase 2RecruitingRush University Medical Center7802023-03-242026-09-09
Effects of E-cigarette Flavors on Youth TCORS 2.0
Flavoring Agents, Nicotine - Nicotine Use Disorder
Phase 1CompletedYale University422022-11-072024-08-09
Oral Cannabidiol for Tobacco Cessation
300 mg Cannabidiol, 600 mg Cannabidiol, Placebo - Tobacco Use, Tobacco Smoking
Phase 1RecruitingJohns Hopkins University502022-11-012026-01-07
Acute Pharmacokinetic and Pharmacodynamic Effects of "Tobacco-Free" Oral Nicotine Pouches in Smokers
Nicotine, Cigarette - Nicotine Withdrawal, Nicotine Addiction
Phase 1CompletedJohns Hopkins University712022-07-272026-07-23
Effects of Menthol in E-cigarettes on Smoking Behaviors
Nicotine - Nicotine Dependence
Phase 1CompletedYale University142022-05-102026-06-16
Adaptive Treatment Strategies for Improving Engagement With a Web-Based Smoking Intervention in Socially Anxious Smokers
Phase 1: Web-based intervention (MyWebQuit) with 1-way text messages, Phase 1: Web-based intervention (MyWebQuit) with interactive, 2-way text messages, Phase 2: re-engagement text messages - Social Anxiety Disorder, Tobacco Use Disorder
Phase 1WithdrawnFred Hutchinson Cancer Center2022-04-152021-12-08
Nicotine Differences in Smokers
0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine, Saline - Nicotine Dependence
Phase 1CompletedYale University112022-02-162023-12-11
CO Monitoring for Tobacco Cessation in Quitlines
Quitline Treatment as Usual (TAU), Remote Carbon Monoxide (CO) Monitoring, Incentivized Remote CO Monitoring - Tobacco Dependence
Phase 1 / Phase 2CompletedConsumer Wellness Solutions2292021-12-312024-10-28
A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers
NicoDerm CQ patch (GSK Dungarvan), NicoDerm CQ (Alza) - Tobacco Use Disorder
Phase 1CompletedHALEON222021-09-012024-03-21
Study of EMB-001 as a Potential Smoking Cessation Treatment
EMB-001 - Tobacco Use Disorder
Phase 1 / Phase 2TerminatedEmbera NeuroTherapeutics, Inc.132021-06-102026-11-05
The Role of Nicotine and Non-Nicotine Alkaloids in E-Cigarette Use and Dependence
E-cigarettes - Nicotine Dependence
Phase 1 / Phase 2CompletedDuke University202021-05-212024-02-21
Development of a mHealth Intervention for Ambivalent Smokers
Control mHealth program, Experimental mHealth program, Nicotine patch - Tobacco Use Disorder, Smoking Cessation
Phase 1CompletedKaiser Permanente572020-12-162023-01-23
The Interaction of Flavor With Nicotine Form in Adult Smokers
Nicotine form, E-cigarette experimental flavor - Nicotine Dependence
Phase 1CompletedYale University202020-11-012023-05-26
Flexiquit+: Web Program to Promote Smoking Cessation in Sexual and Gender Minority Young Adult Smokers
Computer-Assisted Smoking Cessation Intervention, Text Message, Handout - Tobacco Use Disorder
Phase 1CompletedFred Hutchinson Cancer Center252020-05-182020-10-05
Brain Imaging in Tobacco Smokers During a Quit Attempt
[F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide), Contingency Management - Tobacco Use Disorder, Tobacco Smoking
Phase 1CompletedJohns Hopkins University152019-12-162024-08-06
Impact of Nicotine Reduction on Adolescent Cigarette Use, Alternative Tobacco Use, and Harm From Tobacco
Very Low Nicotine Content Cigarettes, Normal Nicotine Content Cigarettes - Nicotine Dependence, Cigarettes, Uncomplicated
Phase 1 / Phase 2CompletedBrown University572019-10-102023-12-19

Showing 20 of 95. Sign in to see all of them.

Narrower conditions

Smoking (23)  ·  Smoking Cessation (17)  ·  Tobacco Use (9)  ·  Substance-Related Disorders (8)  ·  Alcoholism (6)  ·  Cigarette Smoking (5)  ·  Vaping (5)  ·  Marijuana Abuse (3)  ·  Tobacco Smoking (3)  ·  Tobacco Use Cessation (3)  ·  Body Weight (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Alcohol Drinking (1)  ·  Amphetamine-Related Disorders (1)

Broader conditions

Chemically-Induced Disorders (95)  ·  Mental Disorders (94)  ·  Substance-Related Disorders (87)  ·  Behavior (53)  ·  Health Behavior (20)  ·  Smoking (12)  ·  Tobacco Use (7)  ·  Alcohol-Related Disorders (6)  ·  Tobacco Smoking (5)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Signs and Symptoms (3)  ·  Narcotic-Related Disorders (2)  ·  Anxiety Disorders (1)  ·  Arterial Occlusive Diseases (1)  ·  Bipolar and Related Disorders (1)

Interventions

Nicotine (15)  ·  Tobacco Use Cessation Devices (7)  ·  Varenicline (6)  ·  Bupropion (4)  ·  Nicotine Replacement Therapy (3)  ·  Behavior Therapy (2)  ·  Cannabidiol (2)  ·  Counseling (2)  ·  Flavoring Agents (2)  ·  Memantine (2)  ·  Menthol (2)  ·  Naltrexone (2)  ·  Sodium Chloride (2)  ·  Sugars (2)  ·  histaminol (2)

Sponsors

Yale University (17)  ·  National Institute on Drug Abuse (NIDA) (8)  ·  Johns Hopkins University (5)  ·  Boston Children's Hospital (4)  ·  Duke University (4)  ·  Pierre Fabre Medicament (4)  ·  GlaxoSmithKline (3)  ·  McNeil AB (3)  ·  Mclean Hospital (3)  ·  New York State Psychiatric Institute (3)  ·  Star Scientific, Inc (3)  ·  University of Vermont (3)  ·  Brown University (2)  ·  Embera NeuroTherapeutics, Inc. (2)  ·  Fred Hutchinson Cancer Center (2)

Countries

United States (84)  ·  France (4)  ·  China (2)  ·  Canada (1)  ·  Germany (1)  ·  Russia (1)  ·  Spain (1)  ·  Sweden (1)

Top investigators

Maria Varga, MD (5)  ·  Adam Bisaga, M.D. (2)  ·  John R. Knight, MD (2)  ·  Stephen T. Higgins, Ph.D. (2)  ·  Albert Arias, MD (1)  ·  Amanda Mathew, PhD (1)  ·  Amy Janes, PhD (1)  ·  Andrea H. Weinberger, Ph.D. (1)  ·  Annie Umbricht, M.D. (1)  ·  Arthur L. Brody, MD (1)  ·  Benjamin A Toll, Ph.D. (1)  ·  Benjamin A. Toll, Ph.D. (1)  ·  Benjamin A. Toll, PhD (1)  ·  Benjamin Toll, Ph.D. (1)

Results publications

PMID 32628945, PMID 33079196, PMID 34242666, PMID 34255068, PMID 36208817, PMID 38236223, PMID 42560883, PMID 33605440, PMID 17587504, PMID 20056957, PMID 22160487, PMID 22452559, PMID 24821356, PMID 25118794, PMID 25419583, PMID 26476459, PMID 27215559, PMID 27852796, PMID 32297782, PMID 33140460, PMID 34347865, PMID 37142273, PMID 37379059, PMID 39665506, PMID 39834135, PMID 40489161, PMID 40623557

NIH funding

U54DA036151 (4), P50DA036114 (3), P50AA015632 (2), R01DA017572 (2), 271201400069C-0-0-1 (1), 271201500019C-0-0-1 (1), K01DA051882 (1), K23AA020000 (1), K23DA025049 (1), K23DA048181 (1), N01CN35159 (1), P30CA015704 (1), R00DA037276 (1), R01CA140256 (1), R01DA008075 (1)